What is the 13F Pro Quality Score for MRNA?

13F Pro ranks Moderna, Inc. (MRNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MRNA's current score at https://13fpro.ai/research/MRNA (free sign-up required for the full ranking).

Which hedge funds own the most MRNA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MRNA include FMR, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MRNA as soon as new 13F filings post.

Where does 13F Pro source MRNA data?

All Moderna, Inc. fundamentals and ownership data come directly from SEC EDGAR. Moderna, Inc. files with the SEC under CIK 1682852. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MRNA in?

Moderna, Inc. (MRNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MRNA research updated on 13F Pro?

MRNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Moderna, Inc.(MRNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1682852 MRNA stock profile & AI dashboard →

13F Pro Quality Score

15.9/100

Rank #2,743 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

6.3/100

Profitability

5.4/100

Balance Sheet

8.4/100

Earnings Quality

30.0/100

Free Cash Flow

4.8/100

Institutional Flow

16.4/100

Revenue Scale

59.3/100

Dilution Risk

7.5/100

MRNA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Moderna, Inc. (MRNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRNA at 15.9/100 on a 32-signal composite quality model, placing it at rank #2,743 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (4.8) and profitability (5.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Moderna, Inc. reports quarterly revenue of $389.0M, net income of $-1.3B, free cash flow of $-692.0M. Top institutional holders of MRNA by reported 13-F value include FMR, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRNA trades on the Nasdaq exchange and files with the SEC under CIK 1682852. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moderna, Inc. directly from SEC EDGAR. Moderna, Inc.'s 13F Pro composite quality score has ranged between 8 and 91 since 2021, currently 15.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Moderna, Inc.

Quirks, history, and lore behind MRNA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · large-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Revenue surged to roughly $18 billion in its peak year before falling sharply — a boom-bust cycle that made Wall Street's head spin faster than a centrifuge.
3
The History
Founded in 2010, it spent nearly a decade burning cash and building a platform before the world suddenly, urgently, desperately needed exactly what it had been working on.
4
The Secret
Its core technology treats the human body as a software problem — delivering messenger RNA instructions that tell your own cells to build a desired protein.
5
The Lore
It designed its first major product in roughly 48 hours in January 2020, before most people had even heard of the virus it was targeting.
6
The Giveaway
Its COVID-19 vaccine — one of the first two mRNA shots authorized in the U.S. — went into arms worldwide and turned a little-known biotech into a household name overnight.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$389.0M

Net Income

Q1 2026

$-1.3B

Free Cash Flow

Q1 2026

$-692.0M

D/E Ratio

Q1 2026

0.08

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-39.9% YoY

$1.94BFY 2025

FY22 $19.26BFY23 $6.85BFY24 $3.24BFY25 $1.94B

Net Income

+20.8% YoY

$-2.82BFY 2025

FY22 $8.36BFY23 $-4.71BFY24 $-3.56BFY25 $-2.82B

Operating Income

+22.1% YoY

$-3.07BFY 2025

FY22 $9.42BFY23 $-4.24BFY24 $-3.94BFY25 $-3.07B

EPS (Diluted)

+21.8% YoY

$-7.26FY 2025

FY22 $20.12FY23 $-12.33FY24 $-9.28FY25 $-7.26

Total Assets

-12.8% YoY

$12.34BFY 2025

FY22 $25.86BFY23 $18.43BFY24 $14.14BFY25 $12.34B

Total Debt

$590.0MFY 2025

FY22 —FY23 —FY24 $0.00FY25 $590.0M

Op. Cash Flow

+37.6% YoY

$-1.87BFY 2025

FY22 $4.98BFY23 $-3.12BFY24 $-3.00BFY25 $-1.87B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.94B -39.9%	$3.24B -52.7%	$6.85B -64.4%	$19.26B +4.3%	$18.47B +2200.2%	$803.0M
Net Income	$-2.82B +20.8%	$-3.56B +24.5%	$-4.71B -156.4%	$8.36B -31.5%	$12.20B +1733.5%	$-747.0M
Operating Income	$-3.07B +22.1%	$-3.94B +6.9%	$-4.24B -145.0%	$9.42B -29.2%	$13.30B +1842.6%	$-763.0M
EPS (Diluted)	$-7.26 +21.8%	$-9.28 +24.7%	$-12.33 -161.3%	$20.12 -28.9%	$28.29 +1543.4%	$-1.96
Total Assets	$12.34B -12.8%	$14.14B -23.2%	$18.43B -28.7%	$25.86B +4.8%	$24.67B +236.2%	$7.34B
Total Debt	$590.0M	$0.00	—	—	—	—
Operating Cash Flow	$-1.87B +37.6%	$-3.00B +3.7%	$-3.12B -162.6%	$4.98B -63.4%	$13.62B +571.9%	$2.03B

Get alerted when MRNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Moderna, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MRNA

FMR LLC
$2.3B45,672,024 sh
BlackRock, Inc.
$1.5B29,635,876 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2B22,872,458 sh
BAILLIE GIFFORD & CO
$1.0B19,985,876 sh
Capital World Investors
$949.8M18,697,694 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$793.3M15,616,367 sh
STATE STREET CORP
$755.0M14,861,409 sh
GEODE CAPITAL MANAGEMENT, LLC
$478.5M9,435,132 sh
TWO SIGMA INVESTMENTS, LP
$461.6M9,086,404 sh
MORGAN STANLEY
$430.3M8,471,263 sh

Fund	Value	Shares
FMR LLC	$2.3B	45,672,024
BlackRock, Inc.	$1.5B	29,635,876
VANGUARD CAPITAL MANAGEMENT LLC	$1.2B	22,872,458
BAILLIE GIFFORD & CO	$1.0B	19,985,876
Capital World Investors	$949.8M	18,697,694
VANGUARD PORTFOLIO MANAGEMENT LLC	$793.3M	15,616,367
STATE STREET CORP	$755.0M	14,861,409
GEODE CAPITAL MANAGEMENT, LLC	$478.5M	9,435,132
TWO SIGMA INVESTMENTS, LP	$461.6M	9,086,404
MORGAN STANLEY	$430.3M	8,471,263

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MRNA on your watchlist

Track score changes the day Moderna, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MRNA a good stock to buy?

13F Pro's AI-powered analysis of Moderna, Inc. (MRNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRNA are available on the MRNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MRNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Moderna, Inc.'s investment landscape.